Selvigaltin (GB1211), an orally obtainable small molecule galectin-three inhibitor produced to be a therapy for liver fibrosis and cirrhosis, was evaluated to evaluate the effect of hepatic impairment on its pharmacokinetics and security to handle regulatory requirements. Inhibition of galectin-three with GB1211 wasn't relevant to any treatment method- or dose-relevant https://leed332oak6.bloginder.com/profile